
384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen
The Readout Loud
00:00
Recent Acero purchase and liver disease focus
Mike details the Acero acquisition for severe fatty liver (F4 MASH) and its strategic fit.
Play episode from 17:46
Transcript


